CORT
Corcept Therapeutics Incorporated
CORT's fundamentals are strong, but it looks expensive: trading at 58x earnings, about twice its usual 29x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CORT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
CORT's revenue, profitability, cash flow and balance sheet are all currently strong.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CORT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $73.71 | — |
| Cheap | 22x | $27.59 | -63% |
| Fair | 29x | $36.55 | -50% |
| Current | 58x | $73.71 | — |
| Expensive | 59x | $75.21 | +2% |
Historical ranges are pointers, not guarantees.
CORT's PE is in its expensive range at 58x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CORT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
CORT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.42 | +248% |
| Q3 2026 | $1.27 | +46% |
| Q2 2026 | $0.42 | -63% |
| Q1 2026 | $0.35 | -70% |
| Q4 2025 | $0.82 | -33% |
| Q3 2025 | $0.87 | -30% |
| Q2 2025 | $1.12 | 0% |
| Q1 2025 | $1.15 | +9.5% |
| Q4 2024 | $1.23 | +31% |
CORT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $340.5M | +64% |
| Q2 2026 | $256.1M | +32% |
| Q1 2026 | $164.9M | +4.9% |
| Q4 2025 | $202.1M | +11% |
| Q3 2025 | $207.6M | +14% |
| Q2 2025 | $194.4M | +19% |
| Q1 2025 | $157.2M | +7.1% |
| Q4 2024 | $181.9M | +34% |
CORT's revenue has grown year over year for 22 quarters in a row: $340M last quarter, up 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +29 points |
| Q2 2026 | 16% | +2.4 points |
| Q1 2026 | -30% | -32 points |
| Q4 2025 | 2.2% | -12 points |
| Q3 2025 | 4.9% | -21 points |
| Q2 2025 | 14% | -8 points |
| Q1 2025 | 2.2% | -18 points |
| Q4 2024 | 14% | -9.5 points |
CORT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CORT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $142.2M | +161% |
| Q2 2026 | $31M | -29% |
| Q1 2026 | -$17M | -438% |
| Q4 2025 | $38.4M | -35% |
| Q3 2025 | $54.5M | -25% |
| Q1 2025 | $5M | -79% |
| Q4 2024 | $59.2M | +905% |
| Q3 2024 | $72.2M | +37% |
CORT generated $195M in free cash flow over the past year, up 20% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CORT on cash flow, with more consistent year-over-year improvement.
CORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +4.8M shares |
| 1 year | +3.1% | +3.8M shares |
| 3 years | +11% | +12.1M shares |
| 5 years | -1.5% | -1.9M shares |
| Available history | +0.5% | +635K shares |
CORT has 123M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.7M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $42.5M |
| Q2 2025 | $103M |
| Q1 2025 | $27.4M |
| Q4 2024 | — |
CORT has spent almost nothing on buybacks in the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CORT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -13.2x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
CORT has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 3.4 | Oversold |
CORT's weekly RSI is 39 (neutral) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CORT PE vs Healthcare Sector
| Metric | CORT | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 26x | 125% above |
| PE % | 82 | 29 | 53 pts above |
CORT is trading at 58x earnings, a 125% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.1 | 24% below |
| 20 week MA | $102.8 | 28% below |
| 50 week MA | $73.4 | 0.4% above |
| 100 week MA | $71.2 | 3.6% above |
| 200 week MA | $50.5 | 46% above |
CORT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.3 | $27.2 | +121% |
| 2021 | $27.2 | $19.9 | -27% |
| 2022 | $19.9 | $20.7 | +4% |
| 2023 | $20.7 | $32.5 | +57% |
| 2024 | $32.5 | $52.5 | +62% |
| 2025 | $52.5 | $82.7 | +58% |
| 2026 YTD | $82.7 | $73.7 | -11% |
CORT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.